'No occasion' to approach regulators: Religare

The firm said in its communication to the Securities and Exchange Board of India (Sebi), Reserve Bank of India, and the Insurance Regulatory and Development Authority of India (IRDAI), that it would proceed with seeking their approval after the regulators give their decisions on the alleged violations by the Burmans.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news